Saturday 17 October 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.96
0.05
+2.62%
Follow XTLB
| Older periods | Dec '23 | Mar '24 | Sep '24 | Jun '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
9.93 | 11.43 | 0.81 | 0.70 |
Net Debt/EBITDA |
0.00 | 13.37 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 1.81% | 12.04% | |
Debt/Equity |
0.00 | 0.00 | 0.03 | (1.83) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | — | — | |
Interest Coverage |
— | (10.94) | — | — | |
Research and Development Expense of Revenue |
— | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | — | — | |
Intangible Assets out of Total Assets |
0.16 | 0.13 | 0.76 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | — | — | |
Cash per Share |
0.00 | 1.72 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 1.99 | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 1.99 | 0.00 | 0.00 | |
Free Cash Flow |
— | — | — | — | |
Working Capital |
1.84 | 2.33 | (0.48) | (0.23) | |
Net Current Asset Value |
1.84 | 2.33 | (1.58) | (0.23) | |
| Other line items | |||||
Quick Ratio |
9.74 | 11.16 | 0.75 | 0.46 | |
Revenue per Share |
— | 0.00 | — | — | |
Operating CF per Share |
— | 0.00 | — | — | |
Capex per Share |
— | 0.00 | — | — | |
Average Receivables |
— | 0.19 | 0.17 | 0.17 | |
Average Payables |
0.20 | 0.23 | 0.36 | 0.40 | |
Average Assets |
3.31 | 3.13 | 6.07 | 1.69 | |
Average Common Equity |
3.11 | 2.89 | 4.21 | 1.23 |
Columns are period end dates